TY - JOUR
T1 - Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease
AU - Visca, D.
AU - Centis, R.
AU - Pontali, E.
AU - Zampogna, E.
AU - Russell, A. M.
AU - Migliori, G. B.
AU - Andrejak, C.
AU - Aro, M.
AU - Bayram, H.
AU - Berkani, K.
AU - Bruchfeld, J.
AU - Chakaya, J. M.
AU - Chorostowska-Wynimko, J.
AU - Crestani, B.
AU - Dalcolmo, M. P.
AU - D'Ambrosio, L.
AU - Dinh-Xuan, A. T.
AU - Duong-Quy, S.
AU - Fernandes, C.
AU - García-García, J. M.
AU - de Melo Kawassaki, A.
AU - Carrozzi, L.
AU - Martinez-Garcia, M. A.
AU - Martins, P. Carreiro
AU - Mirsaeidi, M.
AU - Mohammad, Y.
AU - Naidoo, R. N.
AU - Neuparth, N.
AU - Sese, L.
AU - Silva, D. R.
AU - Solovic, I.
AU - Sooronbaev, T. M.
AU - Spanevello, A.
AU - Sverzellati, N.
AU - Tanno, L.
AU - Tiberi, S.
AU - Vasankari, T.
AU - Vasarmidi, E.
AU - Vitacca, M.
AU - Annesi-Maesano, I.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - BACKGROUND: The aim of these clinical standards is to provide guidance on 'best practice' care for the diagnosis, treatment and prevention of post-COVID-19 lung disease.METHODS: A panel of international experts representing scientific societies, associations and groups active in post-COVID-19 lung disease was identified; 45 completed a Delphi process. A 5-point Likert scale indicated level of agreement with the draft standards. The final version was approved by consensus (with 100% agreement).RESULTS: Four clinical standards were agreed for patients with a previous history of COVID-19: Standard 1, Patients with sequelae not explained by an alternative diagnosis should be evaluated for possible post-COVID-19 lung disease; Standard 2, Patients with lung function impairment, reduced exercise tolerance, reduced quality of life (QoL) or other relevant signs or ongoing symptoms ≥4 weeks after the onset of first symptoms should be evaluated for treatment and pulmonary rehabilitation (PR); Standard 3, The PR programme should be based on feasibility, effectiveness and cost-effectiveness criteria, organised according to local health services and tailored to an individual patient's needs; and Standard 4, Each patient undergoing and completing PR should be evaluated to determine its effectiveness and have access to a counselling/health education session.CONCLUSION: This is the first consensus-based set of clinical standards for the diagnosis, treatment and prevention of post-COVID-19 lung disease. Our aim is to improve patient care and QoL by guiding clinicians, programme managers and public health officers in planning and implementing a PR programme to manage post-COVID-19 lung disease.
AB - BACKGROUND: The aim of these clinical standards is to provide guidance on 'best practice' care for the diagnosis, treatment and prevention of post-COVID-19 lung disease.METHODS: A panel of international experts representing scientific societies, associations and groups active in post-COVID-19 lung disease was identified; 45 completed a Delphi process. A 5-point Likert scale indicated level of agreement with the draft standards. The final version was approved by consensus (with 100% agreement).RESULTS: Four clinical standards were agreed for patients with a previous history of COVID-19: Standard 1, Patients with sequelae not explained by an alternative diagnosis should be evaluated for possible post-COVID-19 lung disease; Standard 2, Patients with lung function impairment, reduced exercise tolerance, reduced quality of life (QoL) or other relevant signs or ongoing symptoms ≥4 weeks after the onset of first symptoms should be evaluated for treatment and pulmonary rehabilitation (PR); Standard 3, The PR programme should be based on feasibility, effectiveness and cost-effectiveness criteria, organised according to local health services and tailored to an individual patient's needs; and Standard 4, Each patient undergoing and completing PR should be evaluated to determine its effectiveness and have access to a counselling/health education session.CONCLUSION: This is the first consensus-based set of clinical standards for the diagnosis, treatment and prevention of post-COVID-19 lung disease. Our aim is to improve patient care and QoL by guiding clinicians, programme managers and public health officers in planning and implementing a PR programme to manage post-COVID-19 lung disease.
UR - http://www.scopus.com/inward/record.url?scp=85172242385&partnerID=8YFLogxK
U2 - 10.5588/ijtld.23.0248
DO - 10.5588/ijtld.23.0248
M3 - Article
C2 - 37749839
AN - SCOPUS:85172242385
SN - 1027-3719
VL - 27
SP - 729
EP - 741
JO - The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
JF - The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
IS - 10
ER -
